BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonifazi F, Barbato F, Ravaioli F, Sessa M, Defrancesco I, Arpinati M, Cavo M, Colecchia A. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:489. [PMID: 32318059 DOI: 10.3389/fimmu.2020.00489] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Iwai T, Nishida M, Sugita J, Kudo Y, Takasugi R, Yokota I, Takagi R, Shibuya H, Takahashi S, Teshima T. Reliability of an ultrasonographical scoring system for diagnosis of sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation. J Med Ultrason (2001) 2021;48:45-52. [PMID: 33398544 DOI: 10.1007/s10396-020-01071-1] [Reference Citation Analysis]
2 Prabahran A, Koldej R, Chee L, Szer J, Ritchie D. Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01761-z] [Reference Citation Analysis]
3 Luo YH, Yang J, Wei A, Zhu GH, Wang B, Zhang R, Jia CG, Yan Y, Wang K, Li S, Zhou X, Qin MQ, Wang TY. Haploidentical hematopoietic stem cell transplantation for pediatric patients with chronic active Epstein-Barr virus infection: a retrospective analysis of a single center. World J Pediatr 2021;17:626-36. [PMID: 34739695 DOI: 10.1007/s12519-021-00470-9] [Reference Citation Analysis]
4 Sanada Y, Sakuma Y, Onishi Y, Okada N, Hirata Y, Horiuchi T, Omameuda T, Matsumoto K, Lefor AK, Sata N. Prevalence and outcomes of patients with sinusoidal obstruction syndrome after liver transplantation: A ten year's experience of a third-level Centre in Japan. Transpl Immunol 2022;:101557. [PMID: 35218901 DOI: 10.1016/j.trim.2022.101557] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Abinun M, Slatter MA. Haematopoietic stem cell transplantation in paediatric rheumatic disease. Curr Opin Rheumatol 2021;33:387-97. [PMID: 34261117 DOI: 10.1097/BOR.0000000000000823] [Reference Citation Analysis]
6 Andronesi A, Sorohan B, Burcea A, Lipan L, Stanescu C, Craciun O, Stefan L, Ranete A, Varady Z, Ungureanu O, Lupusoru G, Agrigoroaei G, Andronesi D, Iliuta L, Obrisca B, Tanase A. Incidence and Risk Factors for Acute Kidney Injury after Allogeneic Stem Cell Transplantation: A Prospective Study. Biomedicines 2022;10:262. [PMID: 35203472 DOI: 10.3390/biomedicines10020262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kohnken R, Falahatpisheh H, Janardhan KS, Guffroy M. Anatomic and Clinical Pathology Characterization of Drug-Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in Cynomolgus Macaques. Toxicol Pathol 2021;:1926233211037932. [PMID: 34414838 DOI: 10.1177/01926233211037932] [Reference Citation Analysis]
8 Stutz L, Halter JP, Heim D, Passweg JR, Medinger M. Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin. Bone Marrow Transplant 2022. [PMID: 34980902 DOI: 10.1038/s41409-021-01546-w] [Reference Citation Analysis]
9 Akıncı B, Atay D, Demir Yenigürbüz F, Akçay A, Öztürk G. Therapeutic Plasma Exchange in Pediatric Patients With Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease After Hematopoietic Stem Cell Transplantation: A Single-Center Experience. Exp Clin Transplant 2022. [PMID: 35607801 DOI: 10.6002/ect.2021.0475] [Reference Citation Analysis]
10 Elbahlawan L, Bissler J, Morrison RR. Continuous Renal Replacement Therapy: A Review of Use and Application in Pediatric Hematopoietic Stem Cell Transplant Recipients. Front Oncol 2021;11:632263. [PMID: 33718216 DOI: 10.3389/fonc.2021.632263] [Reference Citation Analysis]
11 Mohty M, Cluzeau T, Jubert C, Lawson S, Ryan RJ, Hanvesakul R, Perruccio K. Defibrotide-treated patients with anicteric or icteric veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic cell transplantation: an EBMT study. Bone Marrow Transplant 2022. [PMID: 35115668 DOI: 10.1038/s41409-022-01588-8] [Reference Citation Analysis]
12 Contreras CF, Higham CS, Behnert A, Kim K, Stieglitz E, Tasian SK. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Pediatr Blood Cancer 2021;68:e28718. [PMID: 33098744 DOI: 10.1002/pbc.28718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
13 Otaka F, Ito Y, Goto T, Eshima K, Amano H, Koizumi W, Majima M. Platelets prevent the development of monocrotaline-induced liver injury in mice. Toxicol Lett 2020;335:71-81. [PMID: 33122006 DOI: 10.1016/j.toxlet.2020.10.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Alrubaye RR, Fadel CA, Adewunmi CY, Del Rio Lopez L. Pleural Effusion Secondary to Dasatinib Following Allogenic Hematopoietic Stem Cell Transplantation. Am J Case Rep 2021;22:e932711. [PMID: 34362863 DOI: 10.12659/AJCR.932711] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Robin S, Hassine KB, Muthukumaran J, Jurkovic Mlakar S, Krajinovic M, Nava T, Uppugunduri CRS, Ansari M. A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation. BMC Mol and Cell Biol 2022;23. [DOI: 10.1186/s12860-021-00402-5] [Reference Citation Analysis]
16 Van de Louw A, Twomey K, Habecker N, Rakszawski K. Prevalence of acute liver dysfunction and impact on outcome in critically ill patients with hematological malignancies: a single-center retrospective cohort study. Ann Hematol 2021;100:229-37. [PMID: 32918593 DOI: 10.1007/s00277-020-04197-x] [Reference Citation Analysis]
17 Otaka F, Ito Y, Goto T, Kojo K, Tanabe M, Hosono K, Majima M, Koizumi W, Amano H. Recovery of Liver Sinusoidal Endothelial Cells Following Monocrotaline-induced Liver Injury. In Vivo 2021;35:2577-87. [PMID: 34410945 DOI: 10.21873/invivo.12540] [Reference Citation Analysis]
18 Oikonomopoulou C, Paisiou A, Ioannidou ED, Komitopoulou A, Kaisari A, Zisaki K, Kastamoulas M, Stavroulaki G, Giannakopoulou A, Vessalas G, Kitra-Roussou V, Goussetis E, Peristeri I. Allogeneic hematopoietic stem cell transplantation in infants is associated with significant morbidity and mortality. Pediatr Transplant 2022;:e14239. [PMID: 35122456 DOI: 10.1111/petr.14239] [Reference Citation Analysis]
19 Tilmont R, Yakoub-Agha I, Ramdane N, Srour M, Coiteux V, Magro L, Odou P, Simon N, Beauvais D. Impact of Defibrotide in the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation. Ann Pharmacother 2022;:10600280211068177. [PMID: 35016532 DOI: 10.1177/10600280211068177] [Reference Citation Analysis]
20 Özkan SG, Özkan HA. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: diagnosis, incidence, prophylaxis, and treatment. Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103372] [Reference Citation Analysis]
21 Ravaioli F, Marconi G, Martinelli G, Dajti E, Sartor C, Abbenante MC, Alemanni LV, Nanni J, Rossini B, Parisi S, Colecchia L, Cristiano G, Marasco G, Vestito A, Paolini S, Bonifazi F, Curti A, Festi D, Cavo M, Colecchia A, Papayannidis C. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. Cancer Med 2021. [PMID: 34970853 DOI: 10.1002/cam4.4390] [Reference Citation Analysis]
22 Musial C, Gorska-Ponikowska M. Medical progress: Stem cells as a new therapeutic strategy for COVID-19. Stem Cell Res 2021;52:102239. [PMID: 33601098 DOI: 10.1016/j.scr.2021.102239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hotta M, Satake A, Yoshimura H, Fujita S, Katayama Y, Ota S, Hanamoto H, Oyake T, Ito S, Okada M, Nakanishi T, Ito T, Ishii K, Nomura S. Elevation of Early Plasma Biomarkers in Patients with Clinical Risk Factors Predicts Increased Nonrelapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2021;27:660.e1-8. [PMID: 33989832 DOI: 10.1016/j.jtct.2021.04.025] [Reference Citation Analysis]